Compounded peptides — with the legal basis for every one.
Peptide therapy is the fastest-moving area in compounding, and the most confused. We compound peptides only where a documented §503A basis exists — and we’ll show you that basis for any item on our formulary. The gray market can’t. A LegitScript-certified compounding pharmacy, built for prescribers who want a straight answer.
Two gates decide whether a peptide is compoundable.
Few areas generate more confusion — most of it from a single misconception: that anything “not on FDA’s safety list” is fair game. It isn’t. Compounding requires an affirmative basis, not the mere absence of a prohibition.
Is the bulk substance eligible?
A pharmacy may compound from a bulk drug substance only if it meets one of three conditions:
- It has an applicable USP/NF monograph, or
- It is a component of an FDA-approved drug, or
- It appears on FDA’s 503A bulks list.
Is the finished preparation permissible?
Even when a bulk substance is eligible, a compounded preparation cannot be “essentially a copy” of a commercially available drug product — without a documented, patient-specific clinical difference.
- This matters for any peptide that mirrors an approved drug (e.g., tesamorelin, bremelanotide).
- A different strength, form, route, or a removed allergen can establish the difference.
- The rationale is documented per patient — not assumed.
The straight answer, peptide by peptide.
This is the reference prescribers actually want. Status can change as FDA acts — always confirm the current basis with the pharmacy before prescribing.
| Peptides | Status | Basis / notes |
|---|---|---|
| Sermorelin, Tesamorelin, PT-141 (Bremelanotide) | ✓ Lawful pathway | Component of an FDA-approved drug. Clinical-difference rules apply to the finished compound. |
| Oxytocin, Glutathione, VIP, topical GHK-Cu | ✓ Lawful pathway | Monograph / bulks-list framework. Route limits may apply — GHK-Cu is eligible for non-injectable (e.g., topical) routes only. |
| BPC-157, TB-500, MOTS-C, KPV, Semax, Epitalon | ◷ Under review | No lawful pathway yet. PCAC recommended these for the 503A bulks list (July 2026); awaiting FDA action and rulemaking. |
| Emideltide (DSIP) | ✕ No pathway | Reviewed but not recommended by PCAC (July 2026). |
| CJC-1295, Ipamorelin, Thymosin Alpha-1, MK-677, Kisspeptin, GHRP-2/6, Melanotan | ✕ No pathway | Not nominated / safety category. No lawful pathway at this time. |
§503A covers patient-specific compounding by a pharmacy; §503B covers outsourcing facilities. Bulk-eligibility rules differ between them; the statuses above address §503A. As of January 7, 2025, FDA stopped sorting newly nominated substances into interim categories — new substances now move directly toward PCAC review and bulks-list rulemaking.
A formulary you can defend — with the basis beside every item.
Rather than ask you to take it on faith, we publish the legal basis alongside each peptide. Here are the mainstays; the full Provider Peptide Formulary, with the basis for each item, is available to prescribers on request.
Sermorelin
Approved-drug-component pathway
A growth-hormone-releasing hormone analog that stimulates the body’s own GH release rather than replacing it. Our most-prescribed peptide, in the routes patients prefer.
Tesamorelin
Approved-drug-component pathway
A GHRH analog with an FDA-approved reference product — compounded where a documented, patient-specific clinical difference applies.
PT-141 (Bremelanotide)
Approved-drug-component pathway
A melanocortin-receptor agonist used in sexual-health protocols. Injectable and needle-free forms — see our Sexual Health page for the full set.
Oxytocin
Monograph / approved-drug basis
Compounded in needle-free troche, sublingual, and nasal forms for prescriber-directed protocols.
Glutathione
Monograph / bulks framework
The master antioxidant, compounded in injectable and oral forms for wellness and adjunctive protocols.
GHK-Cu (topical)
Eligible — non-injectable routes
The copper tripeptide for skin and scalp — compounded topically, where it has an eligible route. Injectable GHK-Cu is not covered.
The clearest path peptides have had — but not a green light.
On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list and voted to recommend six. It’s a meaningful step — and it’s a step, not approval.
✓ Recommended
✓ Recommended
✓ Recommended
✓ Recommended
✓ Recommended
✓ Recommended
✕ Not recommended
Why a recommendation isn’t “available”
- 1
PCAC only advises. It reviews the data and recommends; FDA then makes its own decision.
- 2
Listing requires rulemaking. Even a favorable outcome ends in a formal bulks-list placement, which takes more time.
- 3
The copy rule still applies. Eligibility from bulk doesn’t override the “essentially a copy” gate.
- ✓
We add on confirmation, not on a vote. If FDA places a peptide on the bulks list or issues written discretion, we’ll add it — with its documented basis, and not before.
Bottom line: the compounding status of these six has not changed — they are not orderable today. What changed is that they now have a realistic path forward, pending FDA action. The live catalog remains the source of truth for what you can order.
Read the science — not our word for it.
For the peptides we carry, our Learning Center links every claim back to its primary source — labeled by study type, and honest about what’s still preclinical. Source-linked to PubMed and ClinicalTrials.gov, written human-first, refreshed as the research grows.
Evidence you can hand a colleague — because it’s cited, not asserted.
Sermorelin
Order what’s carried — and Roxi keeps you compliant.
The carried peptide formulary lives in FormuConnect, our provider portal — order the form and strength and it flows straight to the bench. Ask Roxi, our built-in AI assistant, about a peptide’s dosing or its legal status, and she answers from our catalog and references — and she won’t offer you something that has no lawful pathway.
- ✓
Order in minutes — carried peptides, with live pricing and tracking to the door.
- ✓
Ask Roxi for dosing and titration — cited, pharmacist-verified — or whether a peptide is even compoundable yet.
- ✓
The catalog is the source of truth — if it’s not carried, it’s not available, regardless of the noise online.
Partner with a compliance-first peptide pharmacy.
A LegitScript-certified 503A pharmacy can show you the legal basis for every peptide it prepares — a research-chemical supplier can’t. Request our Provider Peptide Formulary, with the basis for each item, and we’ll walk you through availability, dosing references, and how ordering works.
Educational information for licensed healthcare providers. Not intended for patient distribution and not a substitute for independent clinical and legal judgment. Formulation Compounding Center is a LegitScript-certified §503A compounding pharmacy; compounded preparations are prepared pursuant to a valid, patient-specific prescription and are not FDA-approved drug products, nor reviewed by the FDA for safety or efficacy. Regulatory statuses described here are current as of July 2026 and are subject to change; the live catalog is the authoritative source of what is available to order. No statement here is a therapeutic claim. Confirm current eligibility, sourcing, and dosing with the FCC pharmacist team at 469-946-6690.